Type 2 Diabetes is a form of Diabetes Mellitus characterised by inadequate insulin action relative to the body's metabolic requirements. Insulin resistance means that tissues such as muscle, liver and adipose tissue respond less effectively to insulin, while pancreatic beta cells initially compensate by producing more insulin. Over time, beta-cell function can become insufficient, resulting in persistent hyperglycaemia. The disorder is influenced by genetics, age, body composition, physical activity, diet, sleep, metabolic history and other factors, so it cannot be accurately explained by a single behavioural cause.
Insulin resistance affects several physiological systems. Skeletal muscle may take up less glucose in response to insulin, the liver may continue producing glucose when suppression would normally occur, and adipose tissue can exhibit altered lipid metabolism and inflammatory signalling. Pancreatic beta cells attempt to compensate through increased insulin secretion, but prolonged metabolic stress can impair their ability to maintain this response. The resulting transition from compensation to overt hyperglycaemia is gradual in many people. This helps explain why abnormal glucose regulation can exist for years before formal diagnosis.
Risk factors for Type 2 Diabetes include increasing age, family history, previous gestational diabetes, certain patterns of body fat distribution, physical inactivity and previous impaired glucose regulation, although no single factor determines whether an individual will develop the disease. Genetic susceptibility is substantial and involves many variants rather than one universal diabetes gene. Social and environmental circumstances can affect access to nutritious food, opportunities for physical activity, healthcare and preventive services. Consequently, population-level diabetes patterns reflect both biological susceptibility and the environments in which people live.
Diagnosis uses measurements such as glycated haemoglobin, fasting plasma glucose or glucose tolerance testing. Because Type 2 Diabetes can be asymptomatic, testing is important in people with appropriate risk profiles rather than waiting for classic symptoms. Early identification can reveal diabetes or intermediate abnormalities in glucose regulation, allowing treatment of hyperglycaemia and cardiovascular risk factors. Interpretation must account for circumstances that affect laboratory measurements, and a diagnosis should follow appropriate clinical criteria rather than being inferred from symptoms alone.
Management commonly combines lifestyle measures with medication according to the individual's glucose levels, cardiovascular and kidney risks, preferences and other clinical characteristics. Nutritional management can involve improving overall dietary quality, controlling energy intake when weight reduction is appropriate, increasing fibre-rich foods and reducing patterns that promote excessive energy intake. Physical activity improves insulin sensitivity and provides cardiovascular and metabolic benefits even when body weight changes little. Medicines may target different aspects of glucose physiology, and some are selected partly for effects on cardiovascular or kidney outcomes.
Type 2 Diabetes is strongly associated with cardiovascular and kidney disease, making risk-factor management an important part of treatment. Blood pressure, lipid levels, smoking, kidney function and other cardiovascular factors may require systematic assessment alongside glucose. Kidney testing can include measurement of urinary albumin and estimation of kidney filtration, while eye and foot assessments can detect complications before symptoms become severe. Effective care therefore focuses on reducing overall disease burden rather than treating the glucose value in isolation.
The term is sometimes incorrectly treated as synonymous with obesity or poor diet. Neither is accurate: people with Type 2 Diabetes have varied body sizes, and genetic and environmental influences are important even when lifestyle is healthy. Conversely, lifestyle changes can substantially reduce risk in many people at increased risk and can improve glucose regulation after diagnosis. Another misconception is that requiring insulin means the original classification was wrong. Some people with Type 2 Diabetes eventually need insulin because progressive beta-cell dysfunction can make endogenous insulin insufficient.
Type 2 Diabetes illustrates the interaction between inherited susceptibility and acquired metabolic physiology. Its progression is not identical in every person, and glucose control can improve considerably when insulin sensitivity, beta-cell workload and other metabolic factors change. Some people achieve remission, particularly following substantial weight loss in appropriate circumstances, but remission does not necessarily mean permanent elimination of underlying susceptibility. Long-term follow-up remains important because metabolic risk can return. Understanding the condition therefore requires distinguishing risk reduction, improved control and remission from the idea of a universal cure.
